CTOs on the Move

Beacon Health Options

www.beaconhealthoptions.com

 
Beacon Health Options is a health improvement company that serves 50 million individuals across all 50 states. On behalf of employers, health plans and government agencies, we manage innovative programs and solutions that directly address the challenges our behavioral health care system faces today. A national leader in the fields of mental and emotional well-being, recovery and resilience, employee assistance, and wellness, Beacon Health Options helps people make the difficult life changes needed to be healthier and more productive. Partnering with a network of providers nationwide, Beacon Health Options helps people take important steps in the right direction. We help ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details
Bryan Marcotte
 VP, Practice Platforms and Corporate Applications Profile
Demarco Smalls
 Chief Information Officer (CIO) Profile
Izhar Mujaddidi
 Vice President, Chief Information Security Officer Profile
Dan Sheehan
 Executive Vice President and Chief Information Officer Profile
Lydia Barron
 SVP and CTO Profile

Similar Companies

The Turnaround Team

The Turnaround Team is a Westfield, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Amalgamated Life and Health

Amalgamated Life and Health is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Virginia Poison Ctr

Virginia Poison Ctr is a Richmond, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DiscoveRx

DiscoveRx is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Fremont, CA. To find more information about DiscoveRx, please visit www.discoverx.com

Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.